FI122520B - Noroviruksen kapsidi ja rotaviruksen VP6-proteiini käytettäväksi yhdistelmärokotteena - Google Patents

Noroviruksen kapsidi ja rotaviruksen VP6-proteiini käytettäväksi yhdistelmärokotteena Download PDF

Info

Publication number
FI122520B
FI122520B FI20106067A FI20106067A FI122520B FI 122520 B FI122520 B FI 122520B FI 20106067 A FI20106067 A FI 20106067A FI 20106067 A FI20106067 A FI 20106067A FI 122520 B FI122520 B FI 122520B
Authority
FI
Finland
Prior art keywords
rotavirus
norovirus
antigen
vaccine
vlp
Prior art date
Application number
FI20106067A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI20106067A0 (fi
Inventor
Vesna Blazevic
Timo Vesikari
Kirsi Nurminen
Leena Huhti
Suvi Lappalainen
Eeva Jokela
Original Assignee
Vesna Blazevic
Timo Vesikari
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vesna Blazevic, Timo Vesikari filed Critical Vesna Blazevic
Publication of FI20106067A0 publication Critical patent/FI20106067A0/fi
Priority to FI20106067A priority Critical patent/FI122520B/fi
Priority to US13/269,326 priority patent/US8895015B2/en
Priority to EP11832191.8A priority patent/EP2627353B1/fr
Priority to PCT/FI2011/050880 priority patent/WO2012049366A1/fr
Priority to SG2013027974A priority patent/SG189398A1/en
Priority to AU2011315405A priority patent/AU2011315405B2/en
Priority to BR112013009164A priority patent/BR112013009164A2/pt
Priority to CN201180049612.4A priority patent/CN103260645B/zh
Priority to KR1020137012218A priority patent/KR101847472B1/ko
Priority to MX2013004159A priority patent/MX352478B/es
Priority to JP2013533249A priority patent/JP5902181B2/ja
Priority to CA2814175A priority patent/CA2814175C/fr
Priority to RU2013121815/10A priority patent/RU2013121815A/ru
Priority to TW100137092A priority patent/TWI479022B/zh
Application granted granted Critical
Publication of FI122520B publication Critical patent/FI122520B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12323—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
FI20106067A 2010-10-14 2010-10-15 Noroviruksen kapsidi ja rotaviruksen VP6-proteiini käytettäväksi yhdistelmärokotteena FI122520B (fi)

Priority Applications (14)

Application Number Priority Date Filing Date Title
FI20106067A FI122520B (fi) 2010-10-15 2010-10-15 Noroviruksen kapsidi ja rotaviruksen VP6-proteiini käytettäväksi yhdistelmärokotteena
US13/269,326 US8895015B2 (en) 2010-10-14 2011-10-07 Norovirus capsid and rotavirus VP6 protein for use as combined vaccine
BR112013009164A BR112013009164A2 (pt) 2010-10-14 2011-10-12 capsídeo de norovírus e proteína vp6 de rotavírus para uso como vacina combinada.
MX2013004159A MX352478B (es) 2010-10-14 2011-10-12 Proteina vp6 de la capside de norovirus y rotavirus para el uso como vacuna combinada.
SG2013027974A SG189398A1 (en) 2010-10-14 2011-10-12 Norovirus capsid and rotavirus vp6 protein for use as combined vaccine
AU2011315405A AU2011315405B2 (en) 2010-10-14 2011-10-12 Norovirus capsid and rotavirus VP6 protein for use as combined vaccine
EP11832191.8A EP2627353B1 (fr) 2010-10-14 2011-10-12 Protéine de capside de norovirus et de rotavirus vp6 a usage comme vaccin combine
CN201180049612.4A CN103260645B (zh) 2010-10-14 2011-10-12 用作联合疫苗的诺罗病毒壳体和轮状病毒vp6蛋白
KR1020137012218A KR101847472B1 (ko) 2010-10-14 2011-10-12 혼합 백신으로 사용하기 위한 노로바이러스 캡시드 및 로타바이러스 ｖｐ6 단백질
PCT/FI2011/050880 WO2012049366A1 (fr) 2010-10-14 2011-10-12 Protéine de capside de norovirus et de rotavirus vp6 a usage comme vaccin combine
JP2013533249A JP5902181B2 (ja) 2010-10-14 2011-10-12 混合ワクチンとして使用するためのノロウイルスカプシド及びロタウイルスｖｐ６タンパク質
CA2814175A CA2814175C (fr) 2010-10-14 2011-10-12 Proteine de capside de norovirus et de rotavirus vp6 a usage comme vaccin combine
RU2013121815/10A RU2013121815A (ru) 2010-10-14 2011-10-12 Капсид норовируса и белок vp6 ротавируса для использования в качестве комбинированной вакцины
TW100137092A TWI479022B (zh) 2010-10-14 2011-10-13 諾羅病毒衣殼與輪狀病毒ｖｐ６蛋白質做為組合疫苗的用途

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20106067A FI122520B (fi) 2010-10-15 2010-10-15 Noroviruksen kapsidi ja rotaviruksen VP6-proteiini käytettäväksi yhdistelmärokotteena
FI20106067 2010-10-15

Publications (2)

Publication Number Publication Date
FI20106067A0 FI20106067A0 (fi) 2010-10-15
FI122520B true FI122520B (fi) 2012-03-15

Family

ID=43064225

Family Applications (1)

Application Number Title Priority Date Filing Date
FI20106067A FI122520B (fi) 2010-10-14 2010-10-15 Noroviruksen kapsidi ja rotaviruksen VP6-proteiini käytettäväksi yhdistelmärokotteena

Country Status (14)

Country Link
US (1) US8895015B2 (fr)
EP (1) EP2627353B1 (fr)
JP (1) JP5902181B2 (fr)
KR (1) KR101847472B1 (fr)
CN (1) CN103260645B (fr)
AU (1) AU2011315405B2 (fr)
BR (1) BR112013009164A2 (fr)
CA (1) CA2814175C (fr)
FI (1) FI122520B (fr)
MX (1) MX352478B (fr)
RU (1) RU2013121815A (fr)
SG (1) SG189398A1 (fr)
TW (1) TWI479022B (fr)
WO (1) WO2012049366A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2559421T3 (es) 2007-03-14 2016-02-12 Takeda Vaccines, Inc. Purificación de partículas similares a virus
CN104024419A (zh) 2011-10-24 2014-09-03 丰田自动车株式会社 使用了重组酵母的乙醇的制造方法
JOP20130186B1 (ar) 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات
CN103667199B (zh) 2012-09-20 2019-01-22 厦门大学 体外制备轮状病毒双层类病毒颗粒的方法
ES2762631T3 (es) * 2013-03-14 2020-05-25 Harvard College Composiciones a base de nanopartículas
EP2971010B1 (fr) 2013-03-14 2020-06-10 ModernaTX, Inc. Formulation et administration de compositions de nucléosides, de nucléotides, et d'acides nucléiques modifiés
JP2015015931A (ja) * 2013-07-12 2015-01-29 株式会社Ｕｍｎファーマ ウイルス様粒子を含む培養物の製造方法
EP3041938A1 (fr) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Polynucléotides circulaires
AU2014315287A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Chimeric polynucleotides
MX2016004249A (es) 2013-10-03 2016-11-08 Moderna Therapeutics Inc Polinulcleotidos que codifican el receptor de lipoproteina de baja densidad.
JP2018078806A (ja) * 2016-11-14 2018-05-24 東ソー株式会社 ノロウイルスｒｎａの検出方法
US11833198B2 (en) 2017-03-28 2023-12-05 Children's Hospital Medical Center Norovirus S particle based vaccines and methods of making and using same
WO2018213731A1 (fr) 2017-05-18 2018-11-22 Modernatx, Inc. Polynucléotides codant pour des polypeptides d'interleukine-12 (il12) ancrés et leurs utilisations
JP6879111B2 (ja) 2017-08-02 2021-06-02 トヨタ自動車株式会社 組換え酵母及びこれを用いたエタノールの製造方法
KR102038364B1 (ko) 2018-03-15 2019-10-30 전남대학교 산학협력단 소 로타바이러스 감염증 예방용 약독화 혼합생백신 조성물
WO2021140524A1 (fr) 2020-01-08 2021-07-15 Bharat Biotech International Limited Compositions de vaccins viraux et leurs méthodes de préparations
CN111265660B (zh) * 2020-01-19 2022-11-15 青岛明勤生物科技有限公司 一种通用型疫苗免疫增强剂
CN114316009B (zh) * 2020-09-29 2023-04-25 上海交通大学 一种能够结合多种病毒的蛋白及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5298244A (en) * 1990-10-25 1994-03-29 University Of Saskatchewan Assembled viral particles and their use in a vaccine to rotaviral disease
IE920366A1 (en) 1991-02-04 1992-08-12 Univ Saskatchewan Vp6 encapsulated drug delivery
US6673355B1 (en) 1995-06-14 2004-01-06 Baylor College Of Medicine Rotavirus enterotoxin NSP4 and methods of using same
JP2000139473A (ja) * 1998-11-16 2000-05-23 Hokkaido Green Bio Kenkyusho:Kk ロタウイルス遺伝子を導入した遺伝子組換え植物、この遺伝子組換え植物に由来するロタウイルスのタンパク質及びこのロタウイルスのタンパク質に対する抗体
US20030166139A1 (en) 2001-07-20 2003-09-04 Choi Anthony H. Rotavirus VP6 subunit
WO2006138514A2 (fr) * 2005-06-16 2006-12-28 Children's Hospital Medical Center Nouvelle particule de norovirus a des fins d'utilisation en tant qu'antiviral ou vaccin
US8168202B2 (en) 2005-07-07 2012-05-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Hexavalent bovine rotavirus reassortant composition designed for use in developing countries
CA2630220C (fr) * 2005-11-22 2020-10-13 Doris Coit Antigenes de norovirus et de sapovirus
ES2559421T3 (es) * 2007-03-14 2016-02-12 Takeda Vaccines, Inc. Purificación de partículas similares a virus
US10130696B2 (en) * 2007-09-18 2018-11-20 Takeda Vaccines, Inc. Method of conferring a protective immune response to norovirus
CA2720210A1 (fr) * 2008-04-18 2009-10-22 Unilever Plc Compositions comprenant des anticorps ou des fragments d'anticorps
WO2010006326A2 (fr) * 2008-07-11 2010-01-14 Tufts University Procédés et compositions pour des vaccins à base de spores
US8486421B2 (en) * 2009-06-09 2013-07-16 Children's Hospital Medical Center Antigen-norovirus P-domain monomers and dimers, antigen-norovirus P-particle molecules, and methods for their making and use

Also Published As

Publication number Publication date
US8895015B2 (en) 2014-11-25
MX352478B (es) 2017-11-27
WO2012049366A1 (fr) 2012-04-19
AU2011315405B2 (en) 2016-09-22
FI20106067A0 (fi) 2010-10-15
EP2627353A4 (fr) 2014-06-18
EP2627353B1 (fr) 2017-11-29
RU2013121815A (ru) 2014-11-20
CA2814175C (fr) 2019-11-05
US20120093884A1 (en) 2012-04-19
CN103260645B (zh) 2016-03-16
KR20140030100A (ko) 2014-03-11
JP2013540773A (ja) 2013-11-07
TW201217530A (en) 2012-05-01
EP2627353A1 (fr) 2013-08-21
CN103260645A (zh) 2013-08-21
JP5902181B2 (ja) 2016-04-13
MX2013004159A (es) 2013-11-04
AU2011315405A1 (en) 2013-05-23
TWI479022B (zh) 2015-04-01
SG189398A1 (en) 2013-05-31
BR112013009164A2 (pt) 2019-09-24
CA2814175A1 (fr) 2012-04-19
KR101847472B1 (ko) 2018-04-11

Similar Documents

Publication Publication Date Title
FI122520B (fi) Noroviruksen kapsidi ja rotaviruksen VP6-proteiini käytettäväksi yhdistelmärokotteena
RU2744193C2 (ru) Иммуногенные композиции для иммунизации свиней против цирковируса типа 3 и способы их получения и применения
Li et al. Virus-like particles for enterovirus 71 produced from Saccharomyces cerevisiae potently elicits protective immune responses in mice
Perrin et al. Recombinant capripoxviruses expressing proteins of bluetongue virus: evaluation of immune responses and protection in small ruminants
AU2020277165B2 (en) Feline calicivirus vaccine
Zhang et al. High-yield production of recombinant virus-like particles of enterovirus 71 in Pichia pastoris and their protective efficacy against oral viral challenge in mice
Xu et al. Superior protection conferred by inactivated whole virus vaccine over subunit and DNA vaccines against salmonid alphavirus infection in Atlantic salmon (Salmo salar L.)
EP1925318A1 (fr) Vaccin à base de virus modifié de vaccin Ankara (MVA) recombinant contre la grippe aviaire
TW201920663A (zh) 免疫原性屈公病毒
CA2673355A1 (fr) Antigenicite des particules sub-virales du virus vp2 de la necrose pancreatique infectieuse exprimees dans la levure
CA2948181A1 (fr) Vaccins a vesicules pseudo-virales (vlv) pour prevenir ou traiter une infection par le virus de l'hepatite b (vhb) chronique
Crisci et al. Chimeric calicivirus-like particles elicit protective anti-viral cytotoxic responses without adjuvant
Farnós et al. High-level expression and immunogenic properties of the recombinant rabbit hemorrhagic disease virus VP60 capsid protein obtained in Pichia pastoris
JP2008528504A (ja) ネコカリシウイルスに対する改良ワクチン
CN108431214B (zh) 人轮状病毒g9p[6]毒株和作为疫苗的用途
EP3583948A1 (fr) Vaccins pour la prévention de la maladie hémorragique du lapin
Farnós et al. Biochemical and structural characterization of RHDV capsid protein variants produced in Pichia pastoris: advantages for immunization strategies and vaccine implementation
WO2013030608A1 (fr) Vaccin vétérinaire à base de nanoparticules
RU2803427C1 (ru) Иммуногенные композиции для иммунизации свиней против цирковируса типа 3 и способы их получения и применения
WO2022076977A1 (fr) Protéine de fusion comprenant une protéine capsidique de circovirus, et particules pseudo-virales chimériques composées de cette dernière
Khaled Calicivirus antigen engineering for possible vaccine development

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 122520

Country of ref document: FI

Kind code of ref document: B